Status:
COMPLETED
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
Lead Sponsor:
Shanghai JMT-Bio Inc.
Conditions:
Giant Cell Tumor of Bone
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvage...
Eligibility Criteria
Inclusion
- 1\. Both genders, aged 18 years or above;
- 2\. Patients pathologically diagnosed of giant cell tumor of bone (GCTB), and are surgically unsalvageable, or salvageable but surgery was associated with severe morbidity based on physician's judgement;
- 3\. For patients received denosumab or other anti-GCTB medications, one of the two is required: imaging data (including X-ray, CT, MRI or PET-CT) prior to and at least once followed to administration, or pathological data on surgically resected GCTB; for patients with no medication, imaging data or pathological data on surgically resected GCTB is required.
Exclusion
- 1\. No access to definite treatment information;
- 2\. Bone metabolic diseases diagnosed before treatment: hypo-/ hyperparathyroidism, hypo-/hyperthyroidism, hypopituitarism, hyperprolactinemia, Cushing syndrome, acromegaly, Paget disease, etc;
- 3\. Complication of malignant tumor receiving anti-tumor therapy.
Key Trial Info
Start Date :
November 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 18 2022
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT05402865
Start Date
November 10 2021
End Date
February 18 2022
Last Update
June 2 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China, 100035
2
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
3
West China Hospital of Sichuan University
Beijing, Beijing Municipality, China, 610044